| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2754279 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 9 Pages |
Abstract
It is likely that increased long-term symptom burden due to side effects of imatinib could contribute to nonadherence. Interventions targeting individual components of QoL may improve adherence and outcomes in CML.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Radhika Unnikrishnan, Surendran Veeraiah, Samson Mani, Rejiv Rajendranath, Swaminathan Rajaraman, Grace Sahaya Vidhubala Elangovan, Venkatraman Radhakrishnan, Trivadi S. Ganesan, Tenali G. Sagar, Prasanth Ganesan,